Steroids and protein-conjugates thereof
US-2024101594-A1 · Mar 28, 2024 · US
US11744903B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11744903-B2 |
| Application number | US-202318187709-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 22, 2023 |
| Priority date | Mar 23, 2022 |
| Publication date | Sep 5, 2023 |
| Grant date | Sep 5, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method for preparing a cyclodextrin metal organic framework (CD-MOF) stable in aqueous phase, including: dissolving β-cyclodextrin and solid potassium hydroxide in deionized water followed by magnetic stirring and ultrasonic treatment at room temperature, addition of methanol and stirring to obtain a reaction mixture; filtering the reaction mixture with a polytetrafluoroethylene membrane filter in a beaker; placing the beaker in methanol vapor to form a β-CD-MOF crystal; washing the β-CD-MOF crystal with ethanol followed by centrifugation and vacuum drying to obtain β-CD-MOF; preparing a β-CD-MOF-active substance complex by impregnation; and preparing an active substance-loaded β-CD-MOF-Tween 80 complex by physical adsorption modification followed by washing with anhydrous ethanol and vacuum drying.
Opening claim text (preview).
What is claimed is: 1. A method for preparing a cyclodextrin metal organic framework (CD-MOF) stable in aqueous phase, comprising: (1) dissolving 0.4254 g of β-cyclodextrin and 0.168 g of solid potassium hydroxide in 15 mL of deionized water followed by magnetic stirring at room temperature for 30 min, ultrasonic treatment at room temperature for 10-15 min, and addition of 9 mL of methanol to obtain a reaction mixture; and stirring the reaction mixture for 5 min for uniform mixing; (2) filtering the reaction mixture with a polytetrafluoroethylene (PTFE) membrane filter to collect a filtrate in a first beaker; (3) placing the first beaker in methanol vapor to form a β-cyclodextrin metal organic framework (β-CD-MOF) crystal; (4) washing the β-CD-MOF crystal 2-3 times with 10-15 mL of ethanol followed by centrifugation at 5000 rpm for 10 min; (5) subjecting the β-CD-MOF crystal to vacuum drying at 40-60° C. for 24 h to remove solvent in channels of the β-CD-MOF crystal to obtain β-CD-MOF; (6) preparing an inclusion complex of an active substance and the β-CD-MOF by impregnation; wherein the active substance is selected from the group consisting of glycitein, naringenin, cinnamaldehyde, tanshinone IIA and resveratrol; (7) preparing a crude active substance-loaded β-CD-MOF-Tween 80 complex stable in aqueous phase by physical adsorption modification; wherein the physical adsorption modification is performed through steps of: adding 0.2-0.6 mL of Tween 80 to a freshly-prepared anhydrous ethanol solution containing the inclusion complex followed by magnetic stirring at 80° C. for 30 min, cooling to room temperature and standing for 48 h to collect a precipitate as the crude active substance-loaded β-CD-MOF-Tween 80 complex; (8) washing the crude active substance-loaded β-CD-MOF-Tween 80 complex 2-3 times with 10-15 mL of anhydrous ethanol followed by vacuum drying at 40-60° C. for 12 h to obtain a purified active substance-loaded β-CD-MOF-Tween 80 complex. 2. The method of claim 1 , wherein the PTFE membrane filter has a pore size of 0.45 μm. 3. The method of claim 1 , wherein step (3) comprises: placing the first beaker in a second beaker containing 40-60 mL of methanol; wherein the second beaker is larger than the first beaker; sealing the second beaker with a pressure-sensitive adhesive; placing the second beaker in a magnetic field generator for 4 h; and placing the second beaker in an electrothermal constant-temperature circulating water bath at 40-60° C. for 12 h to allow methanol to diffuse into the first beaker to obtain the β-CD-MOF crystal. 4. The method of claim 1 , wherein in step (6), the impregnation is performed through steps of: ultrasonically dispersing 20 mg of the β-CD-MOF in 10 mL of anhydrous ethanol to obtain a β-CD-MOF solution; and adding a certain amount of the active substance to the β-CD-MOF solution, followed by stirring at 500 rpm for 1 h and standing for 12 h to obtain the inclusion complex.
using cyclodextrin (cyclodextrins used as simple excipients A61K47/40) · CPC title
Phenols {(cannabinoids A61K31/658)} · CPC title
Aldehydes · CPC title
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title
condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.